echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Preoperative immunotherapy plus chemotherapy improves outcomes in lung cancer patients

    Preoperative immunotherapy plus chemotherapy improves outcomes in lung cancer patients

    • Last Update: 2022-05-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The addition of the immunotherapy drug nivolumab to preoperative (neoadjuvant) chemotherapy in patients with operable non-small cell lung cancer (NSCLC) reduces the risk of cancer recurrence or death by more than three-fold, results from the CheckMate-816 phase III trial show one


    The study, led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, led to Federal Drug Administration (FDA) approval of the first drug for operable non-small cell Immunotherapy/chemotherapy combination therapy in patients with cell lung cancer


    The findings were published online April 11 in the New England Journal of Medicine


    "In this trial, we found that adding nivolumab to standard neoadjuvant chemotherapy reduced the risk of cancer recurrence or death by more than a third


    The standard treatment for resectable lung cancer is surgical removal of the tumor, Ford said


    "We show for the first time that for newly diagnosed patients with stage 1-3 NSCLC, giving immunotherapy before surgery does improve outcomes


    In this study, 358 patients with stage 1B-3A resectable NSCLC were randomly assigned to receive 3 cycles of standard platinum doublet chemotherapy with or without 360 mg of the anti-PD-1 immunotherapy drug nivolumab, followed by surgery


    Pathological complete response was defined as the absence of remaining viable tumor on postoperative examination of lung tumors and lymph nodes


    The current findings build on a small 2018 study by Ford, Drew Pardoll, MD, director of the Bloomberg-Kimmore Cancer Immunotherapy Institute, and Julie Brah.


    "We are excited to add new treatment options to this group of patients, who have historically been difficult to treat," said study co-author Stephen Broderick, MD, MPH, John Hope Associate Director of the Cardiothoracic Surgery Residency Program at Kings University and a thoracic surgeon treating lung cancer patients at the Johns Hopkins Kimmel Cancer Center



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.